Traded Mar 19 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Feb 17, 2026 · Filed Feb 19, 2026
United Therapeutics's PRESIDENT AND COO sold $7.03M of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$7,031,021
Shares × reported transaction price
111 days after results of Oct 29, 2025, 8 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.8% | +0.7% | +4.1% |
| 30 days | +8.5% | −4.3% | +12.7% |
| 90 days | +17.4% | +8.3% | +9.1% |
| 180 days | +7.9% | +12.1% | −4.3% |
Past results only. Not a forecast.
Traded Mar 19 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Martine A Rothblatt (Chairperson & CEO) sold ~$315K of United Therapeutics
Scheduled in advanceMartine A Rothblatt (Chairperson & CEO) sold ~$461K of United Therapeutics
Scheduled in advance